App and Body Fat Scale in the Management of Overweight Patients
NCT05866107 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 204
Last updated 2025-06-05
Summary
This study tests whether using a health app (Huawei Health) and a smart body fat scale can help overweight patients with schizophrenia or bipolar disorder lose weight and stay engaged in their health.
What We're Testing:
1. Patients who use the app and scale for 4 months (Group 1) will lose more weight than those who use them for 2 months (Group 2).
2. Patients who track their weight, diet, and exercise regularly (≥3 times/week) will lose more weight than those who don't.
3. Seeing weight loss results may motivate patients to keep using the app and scale.
How It Works:
Patients weigh themselves weekly with the scale (auto-syncs to the app) and upload dietary log in Huawei Health app. The app will gives personalized diet/exercise tips and tracks progress. Doctors and nutritionists provide extra support through messages.
Goal:
To see if this digital tool + professional support combo works better for long-term weight management.
Conditions
- Schizophrenia
- Bipolar Disorder
- Metabolic Syndrome
- Overweight and Obesity
Interventions
- DEVICE
-
Effectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals with Mental Disorders Using Digital Intervention ("SWIM" trial)
Participants receive a digital-behavioral intervention via Huawei Health App and smart scale: 1. Weekly weigh-ins (auto-synced) 2. Dietary logging (≥3x/week) with calorie-deficit targets 3. Biweekly exercise plans (150-300 min/week) 4. Weekly motivational messages Implementation: Staggered rollout: Batch 1 (Month 3-6), Batch 2 (Month 5-6). Includes 2-week training. Effectiveness monitored via app metrics and adherence. Routine care maintained.
Sponsors & Collaborators
- collaborator INDUSTRY
-
Capital Medical University
lead OTHER
Principal Investigators
-
Le Xiao · Capital Medical University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-31
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
NCT06331286 ·Status: UNKNOWN ·Phase: NA
-
Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients
NCT02644577 ·Status: COMPLETED ·Phase: PHASE4
-
Heart Rate Variability in Response to Metformin Challenge
NCT02500628 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients
NCT06754163 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Anti-psychotic Medication (New Use) Weight Loss Study
NCT01272752 ·Status: WITHDRAWN ·Phase: PHASE2
-
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
NCT00344500 ·Status: COMPLETED ·Phase: NA
-
Monitoring and Management for Metabolic Side Effects of Antipsychotics
NCT01875861 ·Status: COMPLETED ·Phase: NA
-
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
NCT03271866 ·Status: UNKNOWN ·Phase: NA
-
The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
NCT00816907 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
NCT02515773 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
NCT00451399 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
NCT00552500 ·Status: COMPLETED ·Phase: NA
-
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
NCT00167934 ·Status: COMPLETED ·Phase: NA
-
Anti-psychotic Medication (Stable Dose) Weight Loss Study
NCT01272765 ·Status: WITHDRAWN ·Phase: PHASE2
-
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT05744479 ·Status: RECRUITING ·Phase: PHASE4
-
Psychosis and Type 2 Diabetes Study (PODS)
NCT05496907 ·Status: UNKNOWN ·Phase: NA
-
Alleviating the Metabolic Side Effects of Antipsychotic Medications
NCT01567124 ·Status: WITHDRAWN ·Phase: PHASE4
-
Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness
NCT02167620 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative Effectiveness of Dapagliflozin, Metformin, and Lifestyle Modification for Antipsychotic-Induced Weight Gain: An Open-Label Pragmatic Trial
NCT07342764 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity
NCT01384279 ·Status: COMPLETED ·Phase: NA
-
Lifestyle Intervention for Diabetes and Weight Management in Psychosis
NCT01828931 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
NCT05712265 ·Status: COMPLETED ·Phase: PHASE1
-
MetSense Pilot and Feasibility
NCT07264062 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Metformin for Treatment of Antipsychotic-induced Dyslipidemia
NCT01778244 ·Status: COMPLETED ·Phase: PHASE4
-
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
NCT00617240 ·Status: COMPLETED ·Phase: PHASE2